Xiamen Amoytop Biotech Stock Hits Day High with 4.67% Surge

Xiamen Amoytop Biotech Co. has experienced a notable increase of 4.67% on June 29, 2026, reaching an intraday high of CNY 56.00. This performance stands in contrast to the China Shanghai Composite, which rose by 1.16% on the same day. Over the past week, Xiamen Amoytop has shown a gain of 2.99%, while the broader market has declined by 2.14%. Despite a challenging year, where the stock has seen a decline of 23.17%, the company has consistently reported positive results for the last 18 consecutive quarters. Key financial metrics indicate a robust operational performance, with net sales reaching a record CNY 1,216.02 million and an operating profit of CNY 472.2 million. The company boasts a return on equity of 34.50% and a price-to-book ratio of 12.11, reflecting a fair valuation in the current market. While the stock has underperformed compared to the China Shanghai Composite over the past year, its profits have increased by 45.3%, showcasing resilience in its financial health. The company maintains a strong dividend yield of 1.08%, further highlighting its stable financial position within the pharmaceuticals and biotechnology sector.